Mortality of lung cancer as a second primary malignancy: A population-based cohort study
Lei Deng, Hrönn Harðardottír, Huan Song, Zhengrui Xiao, Changchuan Jiang, Qian Wang, Unnur Valdimarsdóttir, Haiying Cheng, Billy W Loo, Donghao Lu, Lei Deng, Hrönn Harðardottír, Huan Song, Zhengrui Xiao, Changchuan Jiang, Qian Wang, Unnur Valdimarsdóttir, Haiying Cheng, Billy W Loo, Donghao Lu
Abstract
Lung cancer as a second primary malignancy (lung-2) is increasingly common, but its prognosis is poorly understood. This study aims to examine the overall and cancer-specific survival of patients diagnosed with lung-2 compared to lung-1. Primary lung cancer patients diagnosed from 1988 to 2014 in the Surveillance, Epidemiology, and End Results (SEER) program were included. Lung-2 was identified in patients with a previous diagnosis of nonlung primary malignancy in SEER. Hazard ratios (HRs) of overall and lung cancer-specific mortality were estimated among patients with lung-2 compared to lung-1, adjusting for age and calendar period at diagnosis, sex, race, socioeconomic status, tumor stage, histology, tumor grade, and treatment. A total of 679 541 and 85 758 patients were identified as lung-1 and lung-2, respectively. Compared to lung-1, patients with lung-2 were more likely to be diagnosed at localized stage, with smaller primary tumor, and treated with surgery. Lung-2 patients were at lower risk of lung cancer-specific mortality in the first 5 years (HR, 0.77; 95% CI, 0.76-0.78 at <1 year; HR, 0.87; 95% CI, 0.86-0.89 from 1 to <5 years) but at higher risk thereafter (HR, 1.32; 95% CI, 1.27-1.37 from 5 to 10 years), independent of tumor characteristics and cancer treatment. Similar pattern was found for overall mortality, although the survival benefit was restricted to the first year after diagnosis. Patients diagnosed with lung-2 face a favorable lung cancer-specific survival within the early period after diagnosis. A conservative approach to manage lung-2 solely based on malignancy history is not supported.
Keywords: cohort study; lung cancer; mortality; prognosis; second primary.
Conflict of interest statement
The authors have declared no conflict of interest.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Figures
References
- Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30:3734‐3745.
- VanderWalde AM, Hurria A. Second malignancies among elderly survivors of cancer. Oncologist. 2011;16:1572‐1581.
- Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182‐192.
- Milano MT, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population‐based study of 187 Hodgkin lymphoma patients. Cancer. 2011;117:5538‐5547.
- Milano MT, Strawderman RL, Venigalla S, Ng K, Travis LB. Non‐small‐cell lung cancer after breast cancer: a population‐based study of clinicopathologic characteristics and survival outcomes in 3529 women. J Thorac Oncol. 2014;9:1081‐1090.
- SEER . 2007 Multiple primary and histology coding rules. 2018. . Accessed February 28, 2018.
- SEER . SEER cause‐specific death classification. 2018. . Accessed January 25, 2018.
- Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9:265.
- Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496‐509.
- Behrens C, Travis LB, Wistuba II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev. 2000;9:1027‐1035.
- Broeks A, Braaf LM, Wessels LF, et al. Radiation‐associated breast tumors display a distinct gene expression profile. Int J Radiat Oncol Biol Phys. 2010;76:540‐547.
- Lorigan P, Califano R, Faivre‐Finn C, Howell A, Thatcher N. Lung cancer after treatment for breast cancer. Lancet Oncol. 2010;11:1184‐1192.
- Prochazka M, Hall P, Gagliardi G, et al. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case‐only design. J Clin Oncol. 2005;23:7467‐7474.
- Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long‐term survivors of Hodgkin's disease: a population‐based evaluation over 25 years. J Clin Oncol. 2002;20:3484‐3494.
- Neugut AI, Murray T, Santos J, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer. 1994;73:1615‐1620.
- Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781‐785.
- Berrington de Gonzalez A, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102:220‐226.
- Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer‐specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population‐based study. J Clin Oncol. 2013;31:930‐937.
- Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer‐registry‐processed cause of death in calculating cancer‐specific survival. Cancer. 2013;119:1900‐1907.
Source: PubMed